Kymera Therapeutics Inc. (KYMR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Kymera Therapeutics Inc. (KYMR) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (57/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+58.8% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How KYMR Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $39.2M | 0% | -891.1% | $311.4M | -$234.3M | -21.3% |
| FY 2024 | $47.1M | 0% | -555.8% | $223.9M | -$207.3M | -26.5% |
| FY 2023 | $78.6M | 44% | -210.6% | $147.0M | -$106.4M | -3.9% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring KYMR)
- ✓Live walkthrough of KYMR's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
KYMR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -16.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KYMR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KYMR. Explore sector supply chains on /butterfly.
KYMR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Kymera Therapeutics Inc. (KYMR)?
In FY 2025 (10-K), KYMR converted $39.2M of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).